Objective: Hypertension is associated with unfavorable changes in adrenergic receptor responsiveness, but the relationship of race and sex to adrenergic receptor responsiveness in the development of cardiovascular disease is unclear. This study examined aadrenergic and ß-adrenergic receptor responsiveness in African-American and white men and women with untreated high blood pressure (BP) (HBP) and with normal BP.
INTRODUCTION
D ownregulation of peripheral b-adrenergic receptor has been documented in animal models of hypertension [1] , and both cardiac and vascular b-adrenergic receptors appear downregulated in human hypertension [2] [3] [4] [5] [6] . Evidence for altered responsiveness of peripheral vascular a-adrenergic receptor in hypertension is less clear. Some studies have reported greater pressor responses to a-adrenergic receptor agonists in hypertensive patients compared with normotensive patients [4, 7] , but others have observed no differences [5, 8] . Human studies of adrenergic receptor responsiveness have frequently been carried out in relatively small [4] [5] [6] [7] 9] , sometimes exclusively normotensive, [10] [11] [12] [13] [14] samples. Nonetheless, sex and race have emerged as important factors to be taken into consideration [5, [12] [13] [14] [15] .
Research is mixed with respect to whether there are sex differences in adrenergic receptor function, with some studies reporting decreased a-adrenergic receptor and b-adrenergic receptor responsiveness in normotensive women compared with men [10] , whereas others have reported increased a-adrenergic receptor responsiveness [11] , greater b-adrenergic receptor responsiveness [12] , or no sex differences in b-adrenergic receptor responsiveness [9, 11] . Although African-Americans appear to have increased a1-adrenergic receptor responsiveness compared with whites [5, 14] , some, but not all [5] , studies have reported reduced b-adrenergic receptor responsiveness in African-Americans compared with white Americans [9, [13] [14] [15] .
Altered adrenergic receptor function plays an important role in the pathophysiology of hypertension and may inform different strategies to treat and prevent high blood pressure (BP) (HBP). Given the sex and racial differences in the prevalence of hypertension [16] [17] [18] , the hemodynamics of hypertension, the rates of uncontrolled hypertension [19, 20] , and the target organ damage associated with hypertension, a more comprehensive understanding of individual differences in adrenergic receptor responsiveness is needed. Although prior studies suggest that sex and race may play a role in adrenergic receptor responsiveness, to our knowledge, no studies have examined the combined effects of BP, race, and sex on the responsiveness of aadrenergic receptor and b-adrenergic receptors in a sample of men and women with unmedicated HBP and with normal BP (NBP).
METHODS

Participants
The study population included 161 men and women, aged 25-45 years, participating in the BIOH study at Duke University Medical Center [21, 22] . The study protocol was approved by Duke University Medical Center's Institutional Review Board, and all participants provided verbal and written consent prior to participation. Individuals with BP exceeding 160 mmHg SBP or 100 mmHg DBP, or a history of antihypertensive medication use, were excluded. Other than HBP, inclusion criteria were designed to establish a study sample in good overall health volunteers with a diagnosis of any other cardiovascular disease, diabetes, or current use of tobacco products were excluded.
Blood pressure screening and classification BP readings were obtained on three separate visits, approximately 1 week apart, to determine BP status. During each visit, participants were asked to relax in a private room for 5 min prior to BP readings. Three seated BPs were taken, 2 min apart, using an appropriate sized occlusion cuff, mercury column sphygmomanometer, and stethoscope. The nine resulting BP readings were averaged to define BP status. Participants whose mean SBP was within the range of 130-160 mmHg and/or whose mean DBP was within the range of 85-100 mmHg over the three screening sessions were classified as having HBP. All other participants, whose BPs were below these ranges, were classified as having NBP.
Cardiovascular measurements during adrenergic receptor responsiveness testing
All adrenergic receptor responsiveness testing was conducted while participants were completely reclined and at least 6 h after the most recent caffeine consumption. BP was measured continuously using the Finapres Model 2300 (Ohmeda, Madison, Wisconsin, USA) noninvasive BP monitor. This instrument utilizes the vascular unloading technique to measure SBP, DBP, and mean arterial pressure (MAP) on a beat-by-beat basis and has been validated against intra-arterial measures under various conditions including pressor responses to phenylephrine [23] . Heart rate (HR) was derived from the ECG as the interval between successive R-waves.
b-Adrenergic receptor responsiveness
The standardized isoproterenol sensitivity test [dose of isoproterenol to increase HR by 25 bpm (CD 25 )] was used to evaluate b-adrenergic receptor responsiveness in terms of the chronotropic dose of isoproterenol required to increase HR by 25 bpm [24] . Progressively, increasing bolus doses of isoproterenol (0.125, 0.25, 0.5, 1.0, 2.0, and 4.0 mg) were injected into a vein until an increase in HR of at least 25 bpm was observed. HR responses following each dose were computed as the shortest three successive ECG R-R intervals following drug injection, compared with the shortest three R-R intervals at rest (preinjection). Following each dose, the next higher dose was not injected for at least 5 min, or until cardiovascular activity had returned to resting levels, usually within 5-l0 min. The linear regression model of log-dose/HR response for each participant was used to determine CD 25 exactly by interpolation. The CD 25 measure provides an index of b-adrenergic receptor responsiveness that is inversely related to adrenergic receptor responsiveness (i.e. higher CD 25 values are indicative of reduced or blunted b-adrenergic receptor responsiveness).
a 1 -Adrenergic receptor responsiveness
A procedure analogous to the b-adrenergic receptor responsiveness test described above was used for assessing a 1 -adrenergic receptor responsiveness, using the a 1 -adrenergic receptor pharmacological agonist phenylephrine, to stimulate vascular a 1 -adrenergic receptor [4] . In this test, the criterion response is defined as the dose required to increase MAP by 25 mmHg (PD 25 ). An initial dose of 25 mg phenylephrine was used, with successive doses doubled until the 25 mmHg response was exceeded, or until a maximum dose of 800 mg. Again, at least 5 min, or longer if required for recovery of MAP to resting levels, preceded administration of successive doses. The linear log-dose/MAP response curve was used to determine the exact PD 25 dose. The PD 25 index is inversely related to vascular a 1 -adrenergic receptor responsiveness (i.e. higher PD 25 indicates reduced a 1 -adrenergic receptor responsiveness, and conversely, lower PD 25 indicates heightened a 1 -adrenergic receptor responsiveness).
Statistical analysis
Data are presented in terms of sample composition (n, %) and as means AE SD (M AE SD). Sample characteristics were compared by BP status, sex, and race. Hierarchical regression analyses were used to evaluate the effect of BP status, sex, and race on b-adrenergic receptor responsiveness to isoproterenol (CD 25 ) and a-adrenergic receptor responsiveness to phenylephrine (PD 25 ). Model 1 included the aforementioned independent variables only, whereas Model 2 also controlled for age and BMI. Exploratory analyses assessed the presence of interactions among BP status, sex, and race. All statistical analyses were conducted using the SAS 9.3 system (SAS Institute, Cary, North Carolina, USA) with significance set at P ¼ 0.05.
RESULTS
Sample characteristics are summarized in Table 1 . The sample was 43% women, 48% African-American, and 45% had HBP. Mean BP in those classified as having HBP was 131/89 AE 8/4 mmHg, compared with 110/71 AE 8/ 5 mmHg for those with NBP.
b-Adrenergic receptor responsiveness
Our initial regression analysis (Model 1) showed that for the CD 25 index, there were significant main effects for BP status
, and a trend for race (b ¼ 0.14, P ¼ 0.07) ( Table 2 ). Participants with HBP had higher CD 25 (reduced b-adrenergic receptor responsiveness) compared with those with NBP, men had significantly higher CD 25 than women, and African-Americans tended to have higher CD 25 compared with whites (Table 3) . When age and BMI were added in Model 2, an additional 6% of the variance in CD 25 was accounted for, that was predominantly due to the effects of BMI (b ¼ 0.23, P ¼ 0.003), with the effects for BP status (b ¼ 0.15, P ¼ 0.054) and race (b ¼ 0.11, P ¼ 0.16) becoming less pronounced (Table 3) . Although there were no significant interaction effects between race, sex, and BP status on badrenergic receptor responsiveness, corresponding CD 25 values adjusted for age and BMI are illustrated in Fig. 1a . Table 2 ). Participants with HBP had lower PD 25 (increased a 1 -adrenergic receptor responsiveness) compared with those with NBP, women had lower PD 25 than men, and African-Americans had significantly lower PD 25 compared with whites (Table 3 ). Neither age (b ¼ À0.04, P ¼ 0.57) nor BMI (b ¼ 0.06, P ¼ 0.44) explained additional variance in PD 25 when included in Model 2, and effects for BP status, sex, and race were virtually unchanged (Table 2) . Although there were no significant interaction effects between race, sex, and BP status on a 1 -adrenergic receptor responsiveness, corresponding PD 25 values adjusted for age and BMI are illustrated in Fig. 1b. 
DISCUSSION
In our biracial sample of men and women, we found that BP status, sex, and race were all associated with differences in [5, 25, 1] . We also observed increased a 1 -adrenergic receptor responsiveness, evidenced by lower PD 25 , in people with HBP compared with those with NBP. Previous studies have shown that postsynaptic b-adrenergic receptor function is attenuated, whereas a 1 -adrenergic receptor functions are potentiated in cardiovascular tissues of hypertensive humans and animals [3, 26] . Reduced b-adrenergic receptor responsiveness and heightened a-adrenergic receptor responsiveness is a likely mechanism contributing to elevated systemic vascular resistance and potential amplification of sympathetic stimulation of the vasculature in hypertension [27] . This pathophysiologic milieu also may promote the development of vascular hypertrophy, leading to a sustained elevation in systemic vascular resistance that is characteristic of established hypertension [27, 28] .
Women, compared with men in our study, demonstrated greater b-adrenergic receptor responsiveness, or lower CD 25 , as well as greater a 1 -adrenergic receptor responsiveness, or lower PD 25 . Although not all studies have found greater a 1 -adrenergic receptor-mediated responses in women [10] , our findings are in keeping with Johansson et al. [29] and Luzier et al. [11] who also reported greater sensitivity to phenylephrine and isoproterenol in women with normal BP. Our observations also are consistent with some [12, 30] , but not all [9, 10] , previous studies of sexrelated differences in b-adrenergic receptor responsiveness. As noted previously, sympathetic nervous system (SNS) hyperactivity results in downregulation of b-adrenergic receptor responsiveness. There is evidence that men exhibit greater resting SNS activity than women, who may more typically show heightened resting parasympathetic activity [31] . It is possible that over time this increased SNS activity may contribute to a greater reduction in b-adrenergic receptor responsiveness at an earlier age in men than in women. Therefore, our observed sex difference in b-adrenergic receptor responsiveness may reflect the smaller agerelated decline in b-adrenergic receptor responsiveness among female compared with male study participants [32] . A significant racial difference was observed for adrenergic receptor responsiveness. African-Americans had reduced b-adrenergic receptor responsiveness coupled with higher a 1 -adrenergic receptor responsiveness compared with white Americans. These findings are supported by the results of previous studies [5, [13] [14] [15] 33] . However, it is of note that controlling for BMI attenuated the race effect for b-adrenergic receptor responsiveness, suggesting that relative body weight was a contributing factor in our study sample. Growing evidence indicates that adrenergic receptor density, distribution and function, and consequent vasomotor activity are determined in part by genetics, accounting for some of the individual differences both between and within racial groups [34, 35] . A recent pharmacogenomics genome-wide meta-analysis of BP responses to b-blockers in African-Americans showed that two genotype variants were related to the antihypertensive efficacy of atenolol and metoprolol [36] . A study examining the effects of b 1 -adrenergic receptor polymorphisms on the response to b-blockade, however, found that racial differences could not be fully explained by different distributions Blood pressure FIGURE 1 Mean dose of isoproterenol to increase heart rate by 25 bpm (mg isoproterenol) and dose of phenylephrine to increase mean arterial pressure by 25 mmHg (mg phenylephrine) by race, sex, and blood pressure status.
of functional b 1 -adrenergic receptor variants [37] . These results suggest that socioeconomic status and lifestyle factors, such as diet, may interact with genetic influences to contribute to racial differences in adrenergic receptor responsiveness.
In contrast to b-adrenergic receptors, a-adrenergic receptors are mainly responsible for sympathetically mediated vasoconstrictive responses [26] . Stein et al. [14] reported that the reduced b-adrenergic receptor responsiveness and increased a-adrenergic receptor responsiveness observed among African-Americans were independent of one another. The additive effects of enhanced vasoconstriction and attenuated vasodilation may amplify vascular tone and vasoconstrictive responses during stressful encounters [14] and may ultimately contribute to the development of the low renin, relatively low cardiac output, and high systemic vascular resistance hemodynamic profile characteristic of African-American hypertensive patients [38] . These physiologic findings and the data from genetic studies are consistent with the clinical observation that men and women of African origin, including African-Americans, derive less benefit than whites and other minorities from the use of beta-blockers [39] [40] [41] [42] .
We also found that increased BMI was related to badrenergic receptor downregulation, contributing to the effects shown in relation to HBP. In addition, controlling for BMI attenuated the race effect for b-adrenergic receptor responsiveness. Previous studies have demonstrated that sympathetic overactivity is a hallmark of obesity and elevated SNS activity is an important pathophysiologic link between obesity and hypertension. However, as others have noted, the precise mechanisms contributing to 'adrenergic overdrive' in obese individuals are complex and not fully understood [43, 44] . Although there were no differences in BMI between African-Americans and whites in our sample, BMI for both groups did meet criteria for classification as overweight. Collectively, these findings suggest that irrespective of race, relative body weight also may be an important contributing factor to diminished b-adrenergic receptor responsiveness.
The current study has several limitations. We employed a cross-sectional design, precluding inferences as to whether race, sex, and BMI differences in adrenergic receptor responsiveness are causally related to the development and progression of hypertensive disease. BP status, in terms of high versus normal, was based upon clinic BP readings only, whereas inclusion of 24-h ambulatory BP monitoring would have allowed for more precise categorization. Other potential factors related to hypertension such as hormonal, metabolic, and psychological status were not evaluated. Similarly, other potential factors contributing to individual differences in adrenergic receptor responsiveness, such as socioeconomic status; alcohol consumption; and dietary salt, sugar, and fat intake were not assessed. Regarding b-adrenergic receptor responsiveness, in our study, criterion response to isoproterenol was the conventional 25 bpm HR response (CD 25 ), reflecting cardiac b-adrenergic receptor responses and not BP or vascular resistance responses, which would be more likely to capture vascular b-adrenergic receptor responsiveness. However, isoproterenol is a nonselective b-adrenergic receptor agonist, and in a previous study we found that the degree of the vasodilatory response of the systemic vasculature was closely related to the magnitude of HR response [5] , suggesting that we may cautiously interpret increased cardiac b-adrenergic receptor responsiveness as also indicative of greater vascular b-adrenergic receptor-mediated vasodilatory responsiveness. We also note that sympathetic and parasympathetic nervous system activity during isoproterenol infusion may also contribute to the measured HR response that is attributed to isoproterenol alone.
In conclusion, the observations from the present study confirm that hypertension is associated with downregulation of cardiovascular b-adrenergic receptor responsiveness. Our findings also indicate that being overweight or obese is likely to contribute to this association. Sex and race were found to be related to the relative responsiveness of a 1 and b-adrenergic receptors and thus potentially influencing the pathophysiology of hypertension. Although heightened a 1 -adrenergic receptor responsiveness occurred in association with HBP, it also was observed to be greater in African-Americans compared with white Americans and in women compared with men. African-Americans are at relatively higher risk for developing hypertension, but younger women are at reduced risk, suggesting that heightened a 1 -adrenergic receptor responsiveness per se is not a likely mechanism or marker of hypertension [18] . In the context of heightened a-adrenergic receptor responsiveness, the accompanying responsiveness of b-adrenergic receptors may be of particular importance. The characteristically higher b-adrenergic receptor responsiveness seen in women may counteract a-adrenergic receptor-mediated vasoconstriction and facilitate vasodilation. However, downregulated b-adrenergic receptor responsiveness may predispose African-Americans to a predominance of a-adrenergic receptor-mediated vasoconstriction. This racial difference in relative a 1 and b-adrenergic receptor responsiveness is exacerbated in the context of HBP and likely contributes to the elevated systemic vascular resistance that is often characteristic of hypertension among African-Americans [45, 46] . This pattern of racial differences in a 1 and b-adrenergic receptor responsiveness may help to inform clinical decision-making in the optimal management of HBP.
Reviewers' Summary Evaluations
Reviewer 1
This investigation demonstrated using pharmacological technique that abnormal responsiveness of beta-adrenergic receptor (ADRB) and alpha1-adrenergic receptors (ADRA1) are closely linked to obesity, BP levels (hypertension), gender and ethnicity. Because this study was performed with a cross-sectional design, the authors could not evaluate which comes first, whether abnormal responsiveness of ADRs or hypertension and/or obesity. However, at least, the findings indicate the contribution of ADRs abnormality to the onset and development of obesity and/or hypertension, as previously reported.
Reviewer 2
This study provides insights into the relevance of the pattern of adrenergic receptor responsiveness in a relatively large cohort of 161 participants of both African American and white background with normal and elevated blood pressure. By examining the responses to both ß-adrenergic and a1-adrenergic stimulation with relevant agonists, the work highlights the association between blunted ß -adrenergic and increased a1-adrenergic responsiveness and early hypertension, particularly in male African Americans. In addition to facilitating a better understanding of the adrenergic mechanisms contributing to the development of hypertension, implications for tailored clinical management may be derived from these data.
